{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:35:48Z","timestamp":1789842948902,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,23]]},"DOI":"10.7759\/cureus.77868","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:09:36Z","timestamp":1737634176000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Thrombocytopenia in the Post-surgical Context and Administration of Factor VIIII (FVIII)\/von Willebrand Factor (VWF) Concentrate in a Patient With von Willebrand Disease Type 2M"],"prefix":"10.7759","author":[{"given":"Daniela","family":"Baptista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louren\u00e7o","family":"Castro e Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Pardal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rebelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2450\/2011.002S","article-title":"Role of von Willebrand factor in the haemostasis","volume":"9 Suppl 2","author":"Peyvandi F","year":"2011","unstructured":"Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus. 2011, 9 Suppl 2:s3-8. 10.2450\/2011.002S","journal-title":"Blood Transfus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"Leebeek FW","year":"2016","unstructured":"Leebeek FW, Eikenboom JC. Von Willebrand's disease. N Engl J Med. 2016, 375:2067-80. 10.1056\/NEJMra1601561","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000272","article-title":"How much do we really know about von Willebrand disease?","volume":"23","author":"Swystun LL","year":"2016","unstructured":"Swystun LL, Lillicrap D. How much do we really know about von Willebrand disease?. Curr Opin Hematol. 2016, 23:471-8. 10.1097\/MOH.0000000000000272","journal-title":"Curr Opin Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04760.x","article-title":"Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: correlation of clinical phenotype with flow-based platelet adhesion","volume":"10","author":"McKinnon TA","year":"2012","unstructured":"McKinnon TA, Nowak AA, Cutler J, Riddell AF, Laffan MA, Millar CM. Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: correlation of clinical phenotype with flow-based platelet adhesion. J Thromb Haemost. 2012, 10:1409-16. 10.1111\/j.1538-7836.2012.04760.x","journal-title":"J Thromb Haemost"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15586","article-title":"Von Willebrand disease type 2M: correlation between genotype and phenotype","volume":"20","author":"Maas DP","year":"2022","unstructured":"Maas DP, Atiq F, Blijlevens NM, et al.. Von Willebrand disease type 2M: correlation between genotype and phenotype. J Thromb Haemost. 2022, 20:316-27. 10.1111\/jth.15586","journal-title":"J Thromb Haemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler JE","year":"2006","unstructured":"Sadler JE, Budde U, Eikenboom JC, et al.. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006, 4:2103-14. 10.1111\/j.1538-7836.2006.02146.x","journal-title":"J Thromb Haemost"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor\/factor VIII concentrate","volume":"15","author":"Berntorp E","year":"2009","unstructured":"Berntorp E, Windyga J. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor\/factor VIII concentrate. Haemophilia. 2009, 15:122-30. 10.1111\/j.1365-2516.2008.01901.x","journal-title":"Haemophilia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2005.11.010","article-title":"Characterisation of a novel high-purity, double virus inactivated von Willebrand factor and factor VIII concentrate (wilate)","volume":"34","author":"Stadler M","year":"2006","unstructured":"Stadler M, Gruber G, Kannicht C, et al.. Characterisation of a novel high-purity, double virus inactivated von Willebrand factor and factor VIII concentrate (wilate). Biologicals. 2006, 34:281-8. 10.1016\/j.biologicals.2005.11.010","journal-title":"Biologicals"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0631","article-title":"Efficacy and safety of a new generation von Willebrand factor\/factor VIII concentrate (Wilate\u00ae) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery","volume":"105","author":"Windyga J","year":"2011","unstructured":"Windyga J, von Depka-Prondzinski M. Efficacy and safety of a new generation von Willebrand factor\/factor VIII concentrate (Wilate\u00ae) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost. 2011, 105:1072-9. 10.1160\/TH10-10-0631","journal-title":"Thromb Haemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12496","article-title":"Safety and efficacy of a von Willebrand factor\/factor VIII concentrate (Wilate\u00ae): a single centre experience","volume":"20","author":"Batty P","year":"2014","unstructured":"Batty P, Chen YH, Bowles L, Hart DP, Platton S, Pasi KJ. Safety and efficacy of a von Willebrand factor\/factor VIII concentrate (Wilate\u00ae): a single centre experience. Haemophilia. 2014, 20:846-53. 10.1111\/hae.12496","journal-title":"Haemophilia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13106","article-title":"Efficacy and safety of a VWF\/FVIII concentrate (wilate(\u00ae) ) in inherited von Willebrand disease patients undergoing surgical procedures","volume":"23","author":"Srivastava A","year":"2017","unstructured":"Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM. Efficacy and safety of a VWF\/FVIII concentrate (wilate(\u00ae) ) in inherited von Willebrand disease patients undergoing surgical procedures. Haemophilia. 2017, 23:264-72. 10.1111\/hae.13106","journal-title":"Haemophilia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2450\/2013.0254-12","article-title":"Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor\/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials","volume":"11","author":"Mannuccio Mannucci P","year":"2013","unstructured":"Mannuccio Mannucci P, Kyrle PA, Schulman S, Di Paola J, Schneppenheim R, Cox Gill J. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor\/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfus. 2013, 11:533-40. 10.2450\/2013.0254-12","journal-title":"Blood Transfus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0465-2","article-title":"Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole)","volume":"58","author":"Hedenmalm K","year":"2002","unstructured":"Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002, 58:265-74. 10.1007\/s00228-002-0465-2","journal-title":"Eur J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.124524","article-title":"Acute renal failure and severe thrombocytopenia associated with metamizole","volume":"25","author":"Redondo-Pachon MD","year":"2014","unstructured":"Redondo-Pachon MD, Enriquez R, Sirvent AE, Millan I, Romero A, Amor\u00f3s F. Acute renal failure and severe thrombocytopenia associated with metamizole. Saudi J Kidney Dis Transpl. 2014, 25:121-5. 10.4103\/1319-2442.124524","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.29315\/gm.v8i1.382","article-title":"Severe thrombocytopenia caused by piperacillin\/tazobactam: a case report","volume":"8","author":"Montezinho S","year":"2021","unstructured":"Montezinho S, Oliveira M, Alves M. Severe thrombocytopenia caused by piperacillin\/tazobactam: a case report. Gaz Med. 2021, 8:.. 10.29315\/gm.v8i1.382","journal-title":"Gaz Med"},{"key":"ref16","article-title":"Immune thrombocytopenia","author":"Pietras NM","year":"2024","unstructured":"Pietras NM, Gupta N, Justiz Vaillant AA, Pearson-Shaver AL. Immune thrombocytopenia. StatPearls. StatPearls Publishing, Treasure Island; 2024."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.868771","article-title":"An update on type 2B von Willebrand disease","volume":"7","author":"Mikhail S","year":"2014","unstructured":"Mikhail S, Aldin ES, Streiff M, Zeidan A. An update on type 2B von Willebrand disease. Expert Rev Hematol. 2014, 7:217-31. 10.1586\/17474086.2014.868771","journal-title":"Expert Rev Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/326577-severe-thrombocytopenia-in-the-post-surgical-context-and-administration-of-factor-viiii-fviiivon-willebrand-factor-vwf-concentrate-in-a-patient-with-von-willebrand-disease-type-2m","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:09:39Z","timestamp":1737634179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/326577-severe-thrombocytopenia-in-the-post-surgical-context-and-administration-of-factor-viiii-fviiivon-willebrand-factor-vwf-concentrate-in-a-patient-with-von-willebrand-disease-type-2m"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.77868","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}